Altimmune (NASDAQ:ALT) Now Covered by William Blair

Research analysts at William Blair assumed coverage on shares of Altimmune (NASDAQ:ALT - Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The firm set a "market perform" rating on the stock.

A number of other brokerages have also commented on ALT. HC Wainwright reissued a "buy" rating and set a $12.00 price target on shares of Altimmune in a research note on Wednesday, February 5th. UBS Group initiated coverage on Altimmune in a research note on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.83.

Altimmune Stock Down 6.1 %

Altimmune stock traded down $0.41 during midday trading on Friday, reaching $6.25. 750,956 shares of the stock traded hands, compared to its average volume of 2,203,163. The stock's fifty day moving average is $6.85 and its 200-day moving average is $7.20. Altimmune has a 12 month low of $5.28 and a 12 month high of $12.35. The stock has a market cap of $444.18 million, a P/E ratio of -4.03 and a beta of 0.19.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. On average, equities analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently modified their holdings of ALT. Ameriprise Financial Inc. raised its holdings in shares of Altimmune by 35.6% in the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after buying an additional 1,378,854 shares during the period. Bellevue Group AG raised its holdings in shares of Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after buying an additional 263,660 shares during the period. Invesco Ltd. raised its holdings in shares of Altimmune by 679.2% in the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after buying an additional 215,375 shares during the period. Millennium Management LLC raised its holdings in shares of Altimmune by 139.8% in the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company's stock worth $2,492,000 after buying an additional 201,484 shares during the period. Finally, Two Sigma Investments LP raised its holdings in shares of Altimmune by 33.2% in the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company's stock worth $4,364,000 after buying an additional 151,001 shares during the period. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.